Insulin Titration System Based on Deep Learning

Sponsor
Shanghai Zhongshan Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05409391
Collaborator
(none)
13
1
1
12
1.1

Study Details

Study Description

Brief Summary

This is an open-labeled, one-arm intervention trial to access the effect and safety of the Insulin Titration System Based on Deep Learning in patients with Type 2 Diabetes Mellitus.

Condition or Disease Intervention/Treatment Phase
  • Device: Insulin Titration System
N/A

Detailed Description

The study enrolls 13 patients with Type 2 Diabetes in Zhongshan Hospital who are on treatment with insulin. After screening for the inclusion and exclusion criteria, eligible patients will receive insulin dosage titration set by the Insulin Titration System Based on Deep Learning in the intervention trial. The goal of insulin therapy was to achieve preprandial capillary blood glucose between 5.6-7.8 mmol/L and postprandial capillary glucose less than 10.0mmol/L. All patients are studied for 5 consecutive days or untill hospital discharge. For each patient, capillary glucose concentration was measured at 7 time points of fasting, after breakfast, before and after lunch, before and after dinner, and before bedtime a day using Glucometer (Glupad, Sinomedisite, China). Capillary glucose measurements were performed by the nurse staff according to standard procedures with a point-of-care testing device, which is integrated into the HIS system. And continuous glucose monitoring (CGM) was performed using flash glucose monitoring (Abbott Freestyle Libre, USA) placed on the upper left arm. This study will be conducted in the Department of Endocrinology, Zhongshan Hospital,Fudan University.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
13 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Study to Assess the Efficacy and Safety of Insulin Titration System Based on Deep Learning on Glucose Control in Type 2 Diabetes Mellitus Patients
Anticipated Study Start Date :
Jun 15, 2022
Anticipated Primary Completion Date :
Jun 15, 2023
Anticipated Study Completion Date :
Jun 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: AI

Insulin Titration System Based on Deep Learning

Device: Insulin Titration System
A noval insulin titration system, which is based on deep learning

Outcome Measures

Primary Outcome Measures

  1. mean daily blood glucose concentration [5 days]

    For each patient, capillary glucose concentration was measured at 7 time points of fasting, after breakfast, before and after lunch, before and after dinner, and before bedtime a day using Glucometer (Glupad, Sinomedisite, China). Capillary glucose measurements were performed by the nurse staff according to standard procedures with a point-of-care testing device, which is integrated into the HIS system. The primary outcome is the difference in glycemia control as measured by mean daily blood glucose concentration during the intervention period.

Secondary Outcome Measures

  1. glucose concentration in target range (TIR) of 3.9-10.0 mmol/L [5 days]

    TIR measured by CGM and Capillary glucose measurements, respectively

  2. glucose concentration above range (10.1-13.9 mmol/L or >13.9 mmol/L) [5 days]

    TAR measured by CGM and Capillary glucose measurements, respectively

  3. glucose concentration below range (3.0-3.8 mmol/L or <3.0 mmol/L) [5 days]

    TBR measured by CGM and Capillary glucose measurements, respectively

  4. glycemic variability [5 days]

    glycemic variability measured by CGM and Capillary glucose measurements, respectively

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • type 2 diabetes

  • age of 18-75 years

  • HbA1c between 7.0% and 11.0%.

Exclusion Criteria:
  • subjects with acute complications of diabetes, such as ketoacidosis or hyperglycemic hyperosmolar state;

  • BMI ≥ 45kg/m2;

  • women who are pregnant or breast-feeding;

  • subjects with severe cardiac, hepatic, renal diseases; subjects with any psychiatric or psychological diseases;

  • subjects with severe edema, infections or peripheral circulation disorders, receiving surgery during hospitalization;

  • subjects who could not comply with the protocol

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Endocrinology, Zhongshan Hospital Fudan University Shanghai China

Sponsors and Collaborators

  • Shanghai Zhongshan Hospital

Investigators

  • Principal Investigator: Xiaoying Li, Shanghai Zhongshan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shanghai Zhongshan Hospital
ClinicalTrials.gov Identifier:
NCT05409391
Other Study ID Numbers:
  • ZSE-202205
First Posted:
Jun 8, 2022
Last Update Posted:
Jun 8, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 8, 2022